WO1999049872A1 - Medicaments preventifs des gastrites alcooliques - Google Patents
Medicaments preventifs des gastrites alcooliques Download PDFInfo
- Publication number
- WO1999049872A1 WO1999049872A1 PCT/JP1999/001509 JP9901509W WO9949872A1 WO 1999049872 A1 WO1999049872 A1 WO 1999049872A1 JP 9901509 W JP9901509 W JP 9901509W WO 9949872 A1 WO9949872 A1 WO 9949872A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- histamine
- famotidine
- alcoholic gastritis
- gastritis
- sucralfate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
Definitions
- the present invention relates to a novel agent for preventing alcoholic gastritis. More particularly the combination of Sukurarufu art and histamine H 2 receptor antagonists, particularly preferably about alcoholic gastritis prophylactic agent characterized by a combination of a Sukurarufu art and famotidine.
- Drinking sickness is experienced once or twice by adults, both men and women. This is mostly due to excessive drinking that exceeds the appropriate amount for oneself, and it is said that the primary metabolite of alcohol, acetoaldehyde, increases in the body.
- a hangover can be said to be a fatigue state in which acute gastritis, an imbalance in body minerals, and dehydration are added to this hangover state. Reducing alcohol consumption is the most effective way to prevent hangovers, but honey, vitamins, and foodstuffs such as liver and yeast, fresh vegetables, It is well known that ingesting lemon and the like is effective.
- Acute gastritis caused by alcohol stimulation of the gastric mucosa has a variety of symptoms, from abdominal discomfort to pain, with nausea and vomiting, and sometimes fever.
- histopathological findings include mucosal edema, loss of superficial epithelium, apparent cell infiltration, erosion and shallow ulcers, and stimulation by gastric juice hypersecretion. Accompanying this, discomfort further increases.
- the present inventors have overcome the gastric disorder during drinking, the results of extensive studies to develop a highly safe alcoholic gastritis agents, cimetidine, ranitidine, nizatidine, mouth Kisachijin, histamine H 2 receptor, such as famotidine
- a highly safe alcoholic gastritis agents cimetidine, ranitidine, nizatidine, mouth Kisachijin, histamine H 2 receptor, such as famotidine
- the present inventors have discovered the novel fact that a combination of a body antagonist and sucralfate, a therapeutic drug for gastrointestinal diseases, can provide a prophylactic agent for alcoholic gastritis that is extremely excellent in both efficacy and safety. It was completed.
- the present invention relates to alcoholic gastritis prophylactic agent, wherein the Conform set the Sukurarufa Bok and histamine H 2 receptor antagonist.
- Figure 1 is a Sukurarufa Bok famotidine 1: 2 (a) or 2: 1 obtained by administering to rats at a ratio of (b), the equivalent showing ED 50 values of the gastric mucosal damage prevention effect of ethanol-induced It is a curve figure.
- the histamine H 2 receptor antagonist used in the present invention refers to a gastric mucosal wall cell that inhibits gastric acid secretion by antagonizing the histamine H 2 receptor, and is useful for gastric ulcer, duodenal ulcer, reflux esophagitis and gastritis. It shows.
- Examples of the histamine H 2 receptor antagonist of the present invention include cimetidine, ranitidine, nizatidine, oral xatidine, and famotidine.
- histamine H 2 receptor antagonists will be described in detail further famotidine as an example, the present invention is not limited thereto.
- sucralfate and famotidine were 2: 1. Or, in the two combinations formulated so as to have a ratio of 1: 2, a remarkable synergistic effect was observed in the ED50 value ( 50 % preventive dose) as shown in Fig. 1.
- sucralfate mixing ratio of the famotidine and 2 in the ED 50 value in the case of 1, famotidine single agent About 1/10 of the time, and about 1/2 of the sucralfate as a single agent, equivalent medicinal effects are observed. Also, with this combination, a remarkable antagonism can be expected in terms of safety.
- the prophylactic agent of the present invention is excellent in both efficacy and safety for determining the value of a drug, and is extremely valuable as a drug.
- the ratio of sucralfate to famotidine is preferably from 0.05 to 10 parts, more preferably from 0.1 to 5 parts, with respect to the former 1 part (parts by weight, hereinafter the same).
- the ratio of sclarfate and famotidine is outside the above range, the synergistic effect described above is not significantly achieved.
- the prophylactic agent of the present invention may further contain an auxiliary agent such as an antacid, a stomachic, a digestive, an intestinal, an analgesic / spasmodic, or another mucosal repair agent as appropriate.
- an auxiliary agent such as an antacid, a stomachic, a digestive, an intestinal, an analgesic / spasmodic, or another mucosal repair agent as appropriate.
- the prophylactic agent of the present invention can be used in various dosage forms such as tablets, granules, powders, capsules, and liquids.
- Rats were fasted for 24 hours and water-free and used as experimental animals.
- both drugs use them in a ratio of 1/3 of sucralfate and 23 of famotidine, or vice versa (ie, 2/3 of sucralfate and 1/3 of famotidine).
- the dose at the time of co-administration was set.
- the high dose, middle dose, and low dose groups are set at a common ratio of 3 for both single administration and combination administration, suspended in a 2% aqueous solution of gum arabic, and orally administered in a volume of 2 m and kg body weight. Received the same volume of the solvent alone. 1 group 1 0 animal to a total 1 3 groups of each three doses with the control group as compared with the same conditions was determined ED 50 values. One hour after the administration of the test drug, 19.5 ml of 99.5% ethanol was orally administered. One hour later, the stomach was excised, and the length of the damage generated in the gastric mucosa was measured. Calculating a sum of the damage per animal was determined ED 50 values of the gastric mucosal damage preventive effect. The results are shown in Table 1 and FIG. These results indicate that the combined use of both drugs exerts a synergistic effect and prevents gastric mucosal damage at low doses.
- the combination preventive agent of the present invention By taking the combination preventive agent of the present invention at the time of drinking about 1 hour before drinking, it is possible to suppress the damage to the gastric mucosa due to alcohol, and to prevent abdominal discomfort and pain due to acute gastritis after drinking. Symptoms can be suppressed.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020007006353A KR20010033001A (ko) | 1998-04-01 | 1999-03-25 | 알콜성 위염 예방제 |
CA002320421A CA2320421A1 (en) | 1998-04-01 | 1999-03-25 | Prophylactic drug for prevention of alcoholic gastritis |
AU29577/99A AU2957799A (en) | 1998-04-01 | 1999-03-25 | Preventives for alcoholic gastritis |
EP99910696A EP1074259A4 (en) | 1998-04-01 | 1999-03-25 | PREVENTIVE MEDICINES FOR ALCOHOLIC GASTRITES |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8867298 | 1998-04-01 | ||
JP10/88672 | 1998-04-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999049872A1 true WO1999049872A1 (fr) | 1999-10-07 |
Family
ID=13949322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/001509 WO1999049872A1 (fr) | 1998-04-01 | 1999-03-25 | Medicaments preventifs des gastrites alcooliques |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1074259A4 (ja) |
KR (1) | KR20010033001A (ja) |
CN (1) | CN1287488A (ja) |
AU (1) | AU2957799A (ja) |
CA (1) | CA2320421A1 (ja) |
WO (1) | WO1999049872A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004175757A (ja) * | 2002-11-28 | 2004-06-24 | Chugai Pharmaceut Co Ltd | 医薬組成物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06502855A (ja) * | 1990-11-27 | 1994-03-31 | ビーチャム・グループ・パブリック・リミテッド・カンパニー | 抗ヒスタミンh↓2受容体拮抗剤および生体接着剤を含有する組成物 |
WO1996015775A1 (en) * | 1994-11-21 | 1996-05-30 | Mcneil-Ppc, Inc. | Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7322394A (en) * | 1993-07-06 | 1995-02-06 | Mcneil-Ppc, Inc. | H2 antagonist-sucralfate-antiflatulent combinations |
-
1999
- 1999-03-25 AU AU29577/99A patent/AU2957799A/en not_active Abandoned
- 1999-03-25 EP EP99910696A patent/EP1074259A4/en not_active Withdrawn
- 1999-03-25 WO PCT/JP1999/001509 patent/WO1999049872A1/ja not_active Application Discontinuation
- 1999-03-25 CA CA002320421A patent/CA2320421A1/en not_active Abandoned
- 1999-03-25 CN CN99801979A patent/CN1287488A/zh active Pending
- 1999-03-25 KR KR1020007006353A patent/KR20010033001A/ko not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06502855A (ja) * | 1990-11-27 | 1994-03-31 | ビーチャム・グループ・パブリック・リミテッド・カンパニー | 抗ヒスタミンh↓2受容体拮抗剤および生体接着剤を含有する組成物 |
WO1996015775A1 (en) * | 1994-11-21 | 1996-05-30 | Mcneil-Ppc, Inc. | Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders |
Non-Patent Citations (3)
Title |
---|
BANK S., ET AL.: "PREVENTION OF DUODENAL ULCERS IN THE RAT USING A COMBINATION OF RANITIDINE AND SUCRALPHATE IN SUBTHERAPEUTIC DOSES.", GUT, BRITISH MEDICAL ASSOCIATION, LONDON,, UK, vol. 26., 1 January 1985 (1985-01-01), UK, pages 603 - 606., XP002922098, ISSN: 0017-5749, DOI: 10.1136/gut.26.6.603 * |
See also references of EP1074259A4 * |
TSUKAMOTO Y., ET AL.: "SHORT REPORT: EFFECT OF SUCRALFATE ON ANGIOGENESIS IN GRANULATION TISSUE OF ACETIC ACID-INDUCED GASTRIC ULCERS IN RATS.", ALIMENTARY PHARMACOLOGY & THERAPEUTICS., BLACKWELL SCIENTIFIC PUBLICATIONS LTD., CAMBRIDGE., GB, vol. 07., 1 January 1993 (1993-01-01), GB, pages 581 - 584., XP002922097, ISSN: 0269-2813 * |
Also Published As
Publication number | Publication date |
---|---|
KR20010033001A (ko) | 2001-04-25 |
CN1287488A (zh) | 2001-03-14 |
AU2957799A (en) | 1999-10-18 |
EP1074259A4 (en) | 2001-06-27 |
CA2320421A1 (en) | 1999-10-07 |
EP1074259A1 (en) | 2001-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5229137A (en) | Methods and pharmaceutical compositions for treating episodic heartburn | |
EP2211845B1 (en) | Glucocorticoid receptor antagonists such as mifepristone for treating cushing's syndrome | |
WO1999053928A1 (en) | Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein | |
JP2012021025A (ja) | メロキシカムを含む組成物 | |
EP0550083B1 (en) | Medicaments for treating inflammatory conditions or for analgesia containing a NSAID and ranitidine bismuth citrate | |
US4766117A (en) | Antiinflammatory compositions and methods | |
PL204075B1 (pl) | Zastosowanie kompozycji farmaceutycznej zawierającej metoklopramid oraz tramadol do wytwarzania leku | |
US4579846A (en) | Antiinflammatory compositions and methods | |
EP2706997B1 (en) | Combinations of solifenacin and pilocarpine for the treatment of overactive bladder | |
EP0190851B1 (en) | Improved antiinflammatory composition | |
CA2036774A1 (en) | Method of reducing serum uric acid and/or increasing renal uric acid clearance with thromboxane synthetase inhibitor and/or thromboxane receptorantagonist or a | |
WO1999049872A1 (fr) | Medicaments preventifs des gastrites alcooliques | |
US4874757A (en) | Antinflammatory compositions and methods | |
KR101153571B1 (ko) | 테나토프라졸 및 히스타민 h2-수용체 길항제를 배합한제약 조성물 | |
JP4203170B2 (ja) | 医薬組成物 | |
KR100208969B1 (ko) | 찹쌀추출물을 함유하는 항궤양제 | |
US4672061A (en) | Antiinflammatory compositions and methods | |
EP0178122B1 (en) | Improved piroxicam-containing antiinflammatory compositions | |
US4812455A (en) | Antiinflammatory compositions and methods | |
KR960011773B1 (ko) | 궤양의 예방 및 치료용 의약 조성물 | |
JP4381585B2 (ja) | 医薬用組成物 | |
JPH0395114A (ja) | 胃および十二指腸の消化性潰瘍の治療薬 | |
JP2023173771A (ja) | 内服用医薬組成物 | |
KR970006084B1 (ko) | 위장질환 치료효과를 갖는 의약 조성물 | |
AU690664B2 (en) | Low dosage ranitidine compositions for the treatment of minor gastrointestinal disorders associated with excess acid secretion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99801979.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) |
Free format text: (EXCEPT GD) |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 29577/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007006353 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999910696 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09582582 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2320421 Country of ref document: CA Ref document number: 2320421 Country of ref document: CA Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1999910696 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007006353 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999910696 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020007006353 Country of ref document: KR |